- •Women aged 35-50 years undergoing screening mammography were categorized by contraceptive exposure during a 2-year lead-in and 7.5-year study period
- •Long-term use of combined oral contraceptives or a levonorgestrel intrauterine device was not associated with an increase in breast density category
- •Initiation of combined oral contraceptives was associated with an increase in breast density category
- •There was no difference in initial breast density in patients exposed to combined oral contraceptives over the lead-in period vs those not exposed
- •Discontinuation of combined oral contraceptives was not associated with a decrease in breast density category
Evaluate the longitudinal relationship between mammographic density and hormonal contraceptive use in late reproductive-aged women.
Patients aged 35–50 years old who underwent 5 or more screening mammograms within a 7.5-year period between 2004 and 2019 in a single urban tertiary care center were randomly selected. Patients were categorized into four cohorts based on hormonal contraceptive exposure during a 2-year lead-in period and a 7.5-year study period: 1) never exposed, 2) always exposed, 3) interval hormonal contraceptive start, and 4) interval hormonal contraceptive stop. The primary outcome was difference in BI-RADS breast density category between initial and final mammograms.
Of the 708 patients included, long-term use of combined oral contraceptives or a levonorgestrel intrauterine device were not associated with an increase in breast density category over the 7.5-year study period, compared to those with no hormonal contraceptive exposure. Initiation of combined oral contraceptives was associated with an increase in breast density category (β = 0.31, P = 0.045); however, no difference in initial density category was noted between those exposed and those never exposed to combined oral contraceptives during the 2-year lead-in period, and discontinuation was not associated with a decrease in breast density category when compared to those with continuous exposure.
Long-term use of combined oral contraceptives or a levonorgestrel intrauterine device was not associated with an increase in BI-RADS breast density category. Initiation of a combined oral contraceptive was associated with an increase in breast density category, although this may be a transient effect.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Imaging
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- ACR BI-RADS atlas, breast imaging reporting and data system.American College of Radiology, Reston, VA2013
- Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations.Radiology. 2002; https://doi.org/10.1148/radiol.2251011667
- Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis.Cancer Epidemiol Biomarkers Prev. 2006; https://doi.org/10.1158/1055-9965.EPI-06-0034
- Heritability of mammographic density, a risk factor for breast cancer.N Engl J Med. 2002; https://doi.org/10.1056/NEJMoa013390
- Association between mammographic density and age-related lobular involution of the breast.J Clin Oncol. 2010; 28: 2207-2212https://doi.org/10.1200/JCO.2009.23.4120
- Mammographic density change with estrogen and progestin therapy and breast cancer risk.J Natl Cancer Inst. 2017; https://doi.org/10.1093/jnci/djx001
- Age-specific trends in mammographic density: the Minnesota breast cancer family study.Am J Epidemiol. 2008; 167: 1027-1036https://doi.org/10.1093/aje/kwn063
- Associations of Oral contraceptives with mammographic breast density in premenopausal women.Cancer Epidemiol Biomarkers Prev. 2022; 31: 436-442https://doi.org/10.1158/1055-9965.EPI-21-0853
- Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.JAMA. 2000; 284: 1791-1798https://doi.org/10.1001/JAMA.284.14.1791
- Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.Cancer Epidemiol Biomarkers Prev. 2005; 14: 350-356https://doi.org/10.1158/1055-9965.EPI-04-0376
- Contemporary hormonal contraception and the risk of breast cancer.N Engl J Med. 2017; 377: 2228-2239https://doi.org/10.1056/NEJMOA1700732/SUPPL_FILE/NEJMOA1700732_DISCLOSURES.PDF
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.Lancet (London, England). 1996; 347: 1713-1727https://doi.org/10.1016/S0140-6736(96)90806-5
- Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history.Clin Breast Cancer. 2018; 18: e15-e24https://doi.org/10.1016/J.CLBC.2017.10.016
- Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices.Eur Radiol. 2022; 32https://doi.org/10.1007/S00330-022-08809-0
- Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis.Acta Obstet Gynecol Scand. 2020; 99: 970-982https://doi.org/10.1111/AOGS.13817
- Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.Contraception. 2012; 86: 345-349https://doi.org/10.1016/J.CONTRACEPTION.2012.01.015
- Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.Fertil Steril. 2014; 101https://doi.org/10.1016/J.FERTNSTERT.2014.03.004
- Ovarian follicular development during the use of oral contraception: a review.J Obstet Gynaecol Can. 2004; 26: 19-24https://doi.org/10.1016/S1701-2163(16)30692-2
- Hormone therapy use and breast tissue DNA methylation: analysis of epigenome wide data from the normal breast study.Epigenetics. 2019; 14: 146-157https://doi.org/10.1080/15592294.2019.1580111
- Association of mammographic density with blood DNA methylation.Epigenetics. 2022; 17: 531-546https://doi.org/10.1080/15592294.2021.1928994
- Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study.Radiology. 1990; 174: 487-490https://doi.org/10.1148/radiology.174.2.2136958
- Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study.Am J Epidemiol. 1991; 134: 1375-1385https://doi.org/10.1093/oxfordjournals.aje.a116041
- Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern.Radiology. 1995; 196: 433-437https://doi.org/10.1148/radiology.196.2.7617857
- Effects of estrogen and estrogen-progestin on mammographic parenchymal density.Ann Intern Med. 1999; 130: 262-269https://doi.org/10.7326/0003-4819-130-4_part_1-199902160-00003
- Mammographic breast density during hormone replacement therapy: differences according to treatment.Am J Obstet Gynecol. 1999; 181 (Mosby Inc): 348-352https://doi.org/10.1016/S0002-9378(99)70560-0
- Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.J Am Med Assoc. 2001; 285: 171-176https://doi.org/10.1001/jama.285.2.171
- Short-term hormone therapy suspension and mammography recall: a randomized trial.Ann Intern Med. 2009; 150: 752-765https://doi.org/10.7326/0003-4819-150-11-200906020-00003
- Effects of a short-term suspension of hormone replacement therapy on mammographic density.Fertil Steril. 2001; 76: 451-455https://doi.org/10.1016/S0015-0282(01)01967-7
- Executive summary of STRAW+10: addressing the unfinished agenda of staging reproductive aging.Climacteric. 2012; 15: 105https://doi.org/10.3109/13697137.2011.650656
- Racial differences in quantitative measures of area and volumetric breast density.J Natl Cancer Inst. 2016; 108https://doi.org/10.1093/JNCI/DJW104
- Mammographic density measured with quantitative computer-aided method: comparison with radiologists' estimates and BI-RADS categories 1.Radiology. 2006; 240https://doi.org/10.1148/radiol.2402041947
- 35. 2015: 316-324https://doi.org/10.1148/RG.352140134 (2) Breast Density: Clinical Implications and Assessment Methods.
- Effects of changes in BI-RADS density assessment guidelines (fourth versus fifth edition) on breast density assessment: intra- and interreader agreements and density distribution.AJR Am J Roentgenol. 2016; 207: 1366-1371https://doi.org/10.2214/AJR.16.16561
- Reader variability in breast density estimation from full-field digital mammograms: the effect of image postprocessing on relative and absolute measures.Acad Radiol. 2013; 20: 560-568https://doi.org/10.1016/J.ACRA.2013.01.003
Published online: March 06, 2023
Accepted: March 1, 2023
Received in revised form: February 25, 2023
Received: August 15, 2022
© 2023 Elsevier Inc. All rights reserved.